# Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

> **NCT03069469** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm
- Pigmented Villonodular Synovitis
- Giant Cell Tumor of Tendon Sheath
- Tenosynovial Giant Cell Tumor
- Tenosynovial Giant Cell Tumor, Diffuse

## Interventions

- **DRUG:** Vimseltinib

## Key facts

- **NCT ID:** NCT03069469
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-16
- **Primary completion:** 2026-07
- **Final completion:** 2028-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069469, "Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03069469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*